Pressurised metered dose inhalers containing solutions of beta-2 agonists

Abstract

The present invention relates to a pressurized measured dose inhaler comprising beta2-agonists. Specifically the invention relates to a medical aerosol preparation which is fed through the pressurized measured dose inhaler. The invention relates to a pharmaceutical formulation for use in the administration of 2(1H)-quinolinone derivative long-acting beta2-agonists by inhalation. Particularly, the invention relates to a chemically stable highly efficient TA 2005 HFA solution formulation to be administered by pressurized metered dose inhalers (pMDIs) characterized by a deep lung penetration. The invention also relates to methods for the preparation of said formulation and to its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

Description

[0001] This application was submitted on February 27, 2003, the application number is 03804972.4, and the title of the invention is "Containing β 2 - Divisional application for a pressurized metered-dose inhaler for a solution of an agonist". Background of the invention

[0002] Asthma is an increasingly common disease and the most common disease in children. It is diagnosed by recurrent stridor and intermittent limitation of ventilation. Despite many advances in its understanding, the condition is poorly understood and often a poorly treated disease. Previously, contraction of airway smooth muscle was considered the most important feature of asthma. There has recently been a marked change in asthma treatment based on the fact that asthma is considered a chronic inflammatory disease. Uncontrolled airway inflammation can lead to mucosal damage and structural changes that irreversibly narrow the airways and fibrillate the lung tissue. change. Treatment therefore aims to cont...

Images